⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6095539 | 0.71 | — | — | |
| SCHEMBL10893086 | 0.69 | — | — | |
| SCHEMBL6095140 | 0.63 | — | — | |
| Hydrochloric Acid SCHEMBL5158572 | 0.63 | — | — | |
| Tert-Butylamine SCHEMBL29112055 | 0.61 | — | — | |
| SCHEMBL1358962 | 0.60 | — | — | |
| SCHEMBL10980922 | 0.58 | — | — | |
| Ammonia Solution, Strong SCHEMBL9300246 | 0.58 | — | — | |
| SCHEMBL13541036 | 0.58 | — | — | |
| Hydrochloric Acid SCHEMBL1359150 | 0.58 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7109352-B2 | Process for producing optically active amino acid derivatives | KANEKA CORPORATION (JP) | 2006-09-19 | — | — | US | disclosed |
| US-20050143586-A1 | Process for producing optically active amino acid derivatives | KANEKA CORPORATION (JP) | 2005-06-30 | — | — | US | disclosed |
| US-6720449-B2 | N-PROTECTING AN OPTICALLY ACTIVE 3-HALOALANINE DERIVATIVE FOLLOWED BY CYCLIZATION FOR AZIRIDINE-2-CARBOXYLIC ACID DERIVATIVES | KANEKA CORPORATION (JP) | 2004-04-13 | — | — | US | disclosed |
| US-20030032814-A1 | Process for preparing optically active amino acid derivatives | KANEKA CORPORATION (JP) | 2003-02-13 | — | — | US | disclosed |
| EP-1179530-A1 | PROCESSES FOR PREPARING OPTICALLY ACTIVE AMINO ACID DERIVATIVES | Kaneka Corporation (JP) | 2002-02-13 | — | — | EP | disclosed |